4.9 (226) · $ 11.50 · In stock
Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/ dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE
Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life. - Abstract - Europe PMC
OUH - Group members
Cancers, Free Full-Text
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open
Lenalidomide, Bortezomib, and Dexamethasone as Induction Therapy Before Autologous Stem Cell Transplant for Multiple Myeloma
Carfilzomib as maintenance therapy after upfront and salvage ASCT
OUH - About our research
167580 PDFs Review articles in MULTIPLE MYELOMA
Health-related quality of life in the ENDEAVOR study: carfilzomib- dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma
Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials - Transplantation and Cellular Therapy, Official Publication of the